Schonfeld Strategic Advisors LLC cut its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 89.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 20,657 shares of the company's stock after selling 166,806 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Syndax Pharmaceuticals were worth $273,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in SNDX. Barclays PLC raised its stake in Syndax Pharmaceuticals by 143.4% during the 3rd quarter. Barclays PLC now owns 187,629 shares of the company's stock valued at $3,612,000 after purchasing an additional 110,535 shares during the period. Assenagon Asset Management S.A. grew its holdings in Syndax Pharmaceuticals by 343.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock valued at $27,292,000 after buying an additional 1,598,428 shares in the last quarter. Inspire Investing LLC raised its position in shares of Syndax Pharmaceuticals by 44.5% during the fourth quarter. Inspire Investing LLC now owns 30,792 shares of the company's stock valued at $407,000 after buying an additional 9,484 shares during the last quarter. KBC Group NV lifted its holdings in shares of Syndax Pharmaceuticals by 104.8% in the fourth quarter. KBC Group NV now owns 6,954 shares of the company's stock worth $92,000 after buying an additional 3,559 shares in the last quarter. Finally, R Squared Ltd purchased a new position in shares of Syndax Pharmaceuticals in the fourth quarter worth $26,000.
Analyst Ratings Changes
Several research firms recently weighed in on SNDX. JPMorgan Chase & Co. raised their target price on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a research note on Thursday, March 20th. Scotiabank lifted their price objective on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the stock a "sector perform" rating in a research note on Tuesday, May 6th. StockNews.com upgraded Syndax Pharmaceuticals to a "sell" rating in a research report on Tuesday, May 6th. HC Wainwright reissued a "buy" rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Finally, Citigroup decreased their price target on shares of Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating on the stock in a research note on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, Syndax Pharmaceuticals has an average rating of "Moderate Buy" and an average target price of $35.91.
Get Our Latest Report on Syndax Pharmaceuticals
Syndax Pharmaceuticals Stock Performance
NASDAQ SNDX traded up $0.10 on Friday, hitting $9.05. 2,954,265 shares of the stock were exchanged, compared to its average volume of 1,719,603. The stock has a fifty day moving average price of $12.18 and a two-hundred day moving average price of $14.17. The firm has a market capitalization of $778.73 million, a P/E ratio of -2.49 and a beta of 0.82. Syndax Pharmaceuticals, Inc. has a 52-week low of $8.58 and a 52-week high of $25.07.
Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to analysts' expectations of $15.88 million. During the same quarter last year, the firm earned ($0.85) EPS. The firm's quarterly revenue was up 1900.0% on a year-over-year basis. Sell-side analysts expect that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current fiscal year.
Syndax Pharmaceuticals Profile
(
Free Report)
Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).
Featured Articles
Before you consider Syndax Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.
While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
